EuroBiotech: More Articles of Note

> The FDA accepted Motif Bio’s filing for approval of the antibiotic iclaprim and granted it priority review status. The status gives iclaprim a PDUFA date of Feb. 13, 2019. Statement

> Izana Bioscience started a phase 2 trial of GM-CSF-targeting antibody namilumab in patients with ankylosing spondylitis. Data from the 40-patient trial are due early next year. Release 

> Crescendo Biologics reached a milestone in its collaboration with Takeda. The milestone marked the delivery of leads against a second target. Statement 

> Adaptimmune Therapeutics got the green light to start dosing patients with up to 6 billion of its MAGE-A4-targeting SPEAR T cells. Statement 

> A1M Pharma shifted its focus to acute kidney injuries after getting a look at preclinical data. The company plans to start a phase 1b of ROSgard in the indication after wrapping up a trial in healthy volunteers next year. Release